Vol.26, Suppl XIII 1999　　Evidence of Off-Label Use of Drug

Contents
Preface	Tsutani K，Shimizu N	iii-iv
Workshop Program		v
Seminar Program		vi
�T．Workshop on Off-label Use of Drug and Evidence 　　　　13 March 1998		1-113
1．Policy of the MHW on this topic	Shiragami M	3-5
2．Off-label use and evidence 　　　　　−Background, purpose and method of the MHW project−	Tsutani K	7-31
3．Evidence and clinical practice	Nagoh N	33-52
4．Evidence and the Cochrane Collaboration	Beppu H	53-65
5．From evidence to clinical guideline	Yoshimura M	67-88
6．Ethnic difference and evidence	Naitoh C	89-106
7．Panel discussion		107-13
�U．Seminar on Off-label Use of Drug 　　　　23 April 1998		115-90
1．Background of the seminar	Shimizu N	117-8
2．Present status and future direction of the off-label use 　　　　　of anti-cancer drugs in Japan	Shimoyama M	119-28
3．Problems encountered in conducting MHW-sponsored clinical trials 　　　　　initiated by the research group of intractable diseases	Miyasaka N	129-38
4．Background and idea of MHW-sponsored study group on the evidence of　　  　　　　　off-label use of drugs for intractable and rare diseases	Iwao S	139-49
5．Research method of MHW-sponsored study group on the evidence of 　　　　　off-label use of drugs for intractable and rare diseases	Tsutani K	151
6．FDA's view on off-label use of drug （6-1Japanese & 6-2English）	Burke L	153-75
7．Panel discussion		177-90
�V．Research report 1997 on the evidence of off-label use 　　 of drugs for intractable and rare diseases	Tsutani K	191-332

Back to Rinsho Hyoka(Clinical Evaluation) home page
Back to Contents